Constrained Peptide Drugs Market is growing fast with CAGR of 90.37%

The global constrained peptide drugs market is anticipated to be valued at $60.1 million in 2023 and is expected to reach $10,367.2 million by 2031, witnessing a CAGR of 90.37% during the forecast period 2023-2031. The market growth in revenue is largely fueled by the promise of a novel breakthrough constrained peptide pipeline, which is no longer restricted to receptor targets. Advancements in chemical technologies, the therapeutics success of commercialized synthetic peptides in recent years, and the affordable pricing being realized by these biomolecules in a wide range of diseases are some additional factors attributing to the projected growth in the forecast period.

Market Segmentation

• Product: BT1718, BT5528, Zilucoplan (RA101495), Rusfertide (PTG-300), PN-943

• Peptide Type: Cyclic Peptides, Disulfide-Rich Peptides (DRPs)

• Region: North America, Europe, Asia-Pacific

Regional Segmentation

• North America – U.S. and Canada

• Europe – U.K., Germany, France, Italy, and Spain

• Asia-Pacific – Japan

Market Growth Drivers

• Enhanced Binding Affinity and Cellular Uptake

• Development of Synthetic Constraining Methods

• Limitations with Conventional Peptides

• Increasing Government and Private Funding

Market Challenges

• Increased Competition from Biologics

• Risk of Immunogenic Effects and Unsatisfactory ADME Properties

Market Opportunities

• Role of Constrained Peptides in Drug Discovery

• Various Application in CNS Disease Studies and Anti-Cancer Therapy

Key Companies Profiled

Aileron Therapeutics, Inc, Bicycle Therapeutics, PLC, Polyphor Limited, Protagonist Therapeutics, Inc, Santhera Pharmaceuticals Holding, Union Chimique Belge S.A. (UCB), Pepscan Therapeutics B.V., Pepticom Ltd., PeptiDream, Inc., CPC Scientific Inc., Creative Peptides, Bio-Synthesis Inc

Request a Sample - https://bisresearch.com/requestsample?id=1195&type=download

Comments

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: • Industry Analysis ...

PP Compound Market for Automotive Industry expected to grow at CAGR of 5.6%

The global PP compound market for automotive industry is expected to reach $17,324.8 million by 2031, with a CAGR of 5.6% during the forecast period 2021-2031. The growth in the market is expected to be driven mainly by the need to reduce the weight of vehicles and demand for cheaper products that can be used in automotive parts. Growth of PP Compound Market for the A utomotive Industry Polypropylene compounds are a kind of resin made from a mixture of one or more base polyolefins. This compound is the base resin that is then mixed with different pigments and additives, which alter the characteristics of the products accordingly depending on the intended use. These polypropylene compounds offer varied applications such as electrical appliances, automotive, building and construction, and furniture components. Benefits of PP Compound Polypropylene can provide some great benefits to manufacturers who use auxiliary parts of cars . For instance, if the ...

Market Research Reports

Search This Blog